Association between first-year virological response to raltegravir and long-term outcomes in treatment-experienced patients with HIV-1 infection.

ABSTRACT:

Background

We explored the relationship between virological response in the first year of treatment and long-term outcomes in the BENCHMRK studies.

Methods

Patients failing antiretroviral treatment with 3-class resistant HIV-1 received double-blinded raltegravir (or placebo) with optimized background therapy (OBT) until week 156, followed by open-label raltegravir with OBT up to week 240. In this exploratory analysis of patients randomized to raltegravir, virological response over weeks 16-48 was categorized as continuous suppression (CS; viral RNA [vRNA] always <50 copies/ml), low-level viraemia (LLV; vRNA always <400 copies/ml, >50 copies/ml at least once), or not suppressed (NS; vRNA >400 copies/ml at least once). The association between these first-year vRNA response cat

SUBMITTER: Eron JJ 

PROVIDER: S-EPMC4422784 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature